Leonardo A Rivera-Rivera1,2, Karly A Cody1, Tobey Betthauser1, Robert V Cadman1, Thomas Reher3, Howard A Rowley3, Cynthia M Carlsson1, Laura Eisenmenger3, Sterling C Johnson1, and Kevin M Johnson2,3
1Department of Medicine, University of Wisconsin-Madison, Madison, WI, United States, 2Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, United States, 3Department of Radiology, University of Wisconsin-Madison, Madison, WI, United States
Synopsis
Cerebrovascular disease (CVD), has been
linked with mild cognitive impairment and dementia stages of Alzheimer’s
disease (AD); however, the question of whether CVD is associated with
underlying AD pathophysiology remains unresolved. There remain many questions
regarding CVD/AD pathophysiology interactions and whether related clinical AD
dementia is enhanced by CVD. In this study, we investigated the relationship
between cardiac and low frequency flow oscillations from 4D-Flow, white matter
hyperintensities (WMHs) from T2 FLAIR MRI, and AD pathology assessed using
β-amyloid (Aβ) and tau PET imaging data.
Introduction:
Recent data suggests a potential compounding influence of
cerebrovascular disease (CVD) on the pathologic trajectory of Alzheimer’s
disease (AD).1 For example, animal studies have shown cardiac
pulsations and vasomotion play a key role in brain clearance of AD related
metabolites.2,3,4,5 A barrier to understanding AD and concomitant CV
pathology is the lack of precise methods to measure vascular degeneration. MRI
is currently used to aid in the characterization of CVD in AD typically based
on the quantification of white matter hyperintensities (WMHs) seen on T2-FLAIR
and cerebral perfusion from arterial spin labeling; however, WMHs and
hypo-perfusion occur in other diseases and in normal aging. Intracranial 4D-Flow
MRI is a technique with the ability to provide complementary vessel information
to these measures. Using newly developed
acquisition and reconstruction strategies, 4D-Flow MRI hemodynamic
alterations have been observed in subjects diagnosed with AD clinical syndrome6;
however, a syndrome is not an etiology.7 Clinical AD diagnoses often
differ significantly (>35%) from final neuropathological diagnoses.8
Therefore, to study the relationship between CVD and AD, AD biomarker data are
necessary. In this study we investigated the relationship between 4D-Flow and
T2-FLAIR vascular markers including high frequency cardiac pulsations and low
frequency oscillations (LFOs) and WMHs with AD biomarkers of β-amyloid
deposition and neurofibrillary tau tangles using 11C-PiB and 18F-MK-6240
PET in both preclinical and clinical AD.Methods:
Subjects: A total of 115
subjects participated in this study (fig1). Subjects were clinically
cognitively normal, except those in the impaired group A+/T+/IM (IM; impaired,
n=9 MCI, n=5 AD). MRI: Whole brain
4D-Flow data were acquired on a 3.0T system (MR750, GE Healthcare) using a
32-channel head coil with a 3D radially undersampled sequence and the following
imaging parameters Venc=80cm/s, imaging volume=22x22x16cm3,
TR/TE=7.7/2.5ms, scantime~6.35min.9 To characterize LFOs 4D-Flow
data were retrospectively reconstructed to absolute time using GPU accelerated
(SigPy)10 iterative SENSE with JSENSE11 sensitivity maps
and a local-low rank temporal constraint12. Reconstructions were
performed with block shifting of a 16x16x16 block and an empirically tuned
regularization parameter (λ=0.0001). Velocity data time series were reconstructed
into 100 frames (temporal res ~3.8s, spatial res ~1.72mm3) and
rigidly registered. In addition, 4D-Flow MRI data were also reconstructed with
gating to the cardiac cycle (temporal res ~50ms, spatial res ~0.7mm3).
This was done to characterize high frequency cardiac pulsations. Background
phase and velocity aliasing corrections were performed.13
Intracranial arteries including internal carotid arteries (ICAs) and veins
(superior sagittal sinus (SSS)) were segmented automatically in MATLAB (Mathworks,
Natick, MA).14 Quantified flow parameters included: total cerebral
blood flow, trans-capillary pulse wave delay, low frequency flow range and
standard deviations, and LFOs from power spectral analysis. Trans-capillary
pulse wave delay was defined as the time shift between arterial and venous
cardiac waveforms measured from time-to-upstroke (maximum acceleration).15
Intracranial volumes (ICVs), CSF and hippocampal volume were segmented using
T1-weighted data, SPM1216 and FSL FIRST17. WMHs lesion
volumes were segmented from 3D T2-FLAIR images using a lesion segmentation tool
for SPM12.18 PET: Amyloid
and tau burden were assessed using 11C-PiB and 18F-MK-6240
PET, respectively.19 Three biomarker groups were established (A-T-,
A+T-, A+T+) based on PET biomarker positivity, where amyloid positivity was
determined using a previously established global PiB distribution volume ratio
(DVR) threshold >1.19 and tau positivity was determined using a previously
established entorhinal cortex MK-6240 standard uptake value ratio (SUVR)
threshold >1.27.19,20 Pairwise statistical differences were
assessed using ANOVA followed by post hoc analysis using the Tukey‐Kramer method (P<0.05
significance).Results:
Demographics, cardiovascular and AD biomarkers are summarized in figure
1. No significant AT biomarker group differences were observed across
traditional cardiovascular and cerebrovascular metrics, including WMH lesion
volumes. Cerebral blood flow was similar between AT groups (fig2 a); however,
ICA trans-capillary pulse wave delay was significantly longer in controls when
compared with AD biomarker confirmed groups (fig2 b) including cognitively
normal and impaired amyloid and tau positive groups (P<0.001, P<0.001,
P<0.001). Low frequency flow range and standard deviations in the ICA were
significantly lower in AT positive groups both cognitively normal and impaired
(fig3 a, b) (P=0.024, P=0.034). ICA and SSS LFOs were diminished in groups both
amyloid and tau positive when compared to controls and amyloid positive only
groups (fig 4). Overall, linear regression analysis showed a relatively weak
correlation between ICA trans-capillary pulse wave delay and PiB and MK-6240 (R2=0.12,
R2=0.03), and low frequency blood flow standard deviation and PiB
and MK-6240 (R2=0.06, R2=0.04) (fig5.).Discussion and Conclusions:
Although more traditional measures of CVD were not related to biomarker
groups, high frequency cardiac-resolved MRI suggests alterations in the
cerebrovasculature are occurring in AD biomarker positive subjects during
preclinical stage (e.g. A+/T-/CN, A+/T+/CN). The significantly shorter
trans-capillary pulse wave delay might be an indicator of underlying AD
pathology related artery and capillary stiffening and diminished caliber
changes.21 In addition, low frequency time-resolved MRI showed
decreased LFO content in amyloid+tau positive subjects, but not in A+ only.
This result suggests compounding cerebrovascular modifications in amyloid+tau
positive subjects related to changes in vessel smooth muscle cell, vasomotion
and decreased autoregulation.22 4D-Flow measures were noisy and thus
require acquisition and reconstruction improvements. Studies investigating interactions
between vascular measures and AD biomarkers on cognitive trajectories are
ongoing.Acknowledgements
We gratefully acknowledge research support from GE Healthcare, and
funding support from the Alzheimer's Association (AARFD-20-678095) and from NIH
grants R01NS066982, P50-AG033514, and R01AG021155.References
- Sweeney MD, Montagne A, Sagare AP, et
al. Vascular dysfunction-the disregarded partner of Alzheimer's disease.
Alzheimer's Dementia 2019,15 (1), 158–167.
- Hawkes CA, Jayakody N, Johnston DA,
et al. Failure of Perivascular Drainage of β-amyloid in Cerebral Amyloid
Angiopathy: Failure of Perivascular Drainage of β-amyloid. Brain Pathology
2014; 24: 396–403.
- Carare RO, Aldea R, Bulters D, et al.
Vasomotion Drives Periarterial Drainage of Aβ from the Brain. Neuron 2020; 105:
400–401.
- van Veluw SJ, Hou SS, Calvo-Rodriguez
M, et al. Vasomotion as a Driving Force for Paravascular Clearance in the Awake
Mouse Brain. Neuron 2020; 105: 549-561.e5.
- Mestre H, Tithof J, Du T, et al. Flow
of cerebrospinal fluid is driven by arterial pulsations and is reduced in
hypertension. Nature Communications; 9. Epub ahead of print December 2018. DOI:
10.1038/s41467-018-07318-3.
- Rivera-Rivera LA, Cody KA, Rutkowski
D, et al. Intracranial vascular flow oscillations in Alzheimer’s disease from
4D flow MRI. NeuroImage: Clinical 2020; 28: 102379.
- Jack
Jr CR, Bennett DA, Blennow K et al. NIA-AA Research Framework: Toward a
biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr; 14(4):535-562.
doi: 10.1016/j.jalz.2018.02.018.
- Selvackadunco
S, Langford K, Shah Z, et al. Comparison of clinical and neuropathological
diagnoses of neurodegenerative diseases in two centres from the Brains for
Dementia Research (BDR) cohort. J Neural Transm (Vienna). 2019; 126(3):
327–337.
- Johnson KM, Lum DP, Turski PA, et al.
Improved 3D Phase Contrast MRI with Off-resonance Corrected Dual Echo VIPR.
Magn Reson Med. 2008 Dec; 60(6): 1329–1336.
- Ong F, Lustig M. SigPy: A Python
Package for High Performance Iterative Reconstruction. 27th Annual ISMRM
Meeting, Montreal, Canada, p. 4819.
- Ying L, Sheng J. Joint image
reconstruction and sensitivity estimation in SENSE (JSENSE). Magn Reson Med.
2007 Jun;57(6):1196-202.
- Jimenez JE, Strigel RM, Johnson KM,
et al. Feasibility of high spatiotemporal resolution for an abbreviated 3D
radial breast MRI protocol. Magn Reson Med. 2018 Oct;80(4):1452-1466.
- Loecher M, Schrauben E, Johnson KM,
et al. Phase unwrapping in 4D MR flow with a 4D single-step laplacian
algorithm. J Magn Reson Imaging 2016; 43: 833–842.
- Schrauben E, Wåhlin A, Ambarki K, et
al. Fast 4D flow MRI intracranial segmentation and quantification in tortuous
arteries. J Magn Reson Imaging. 2015 Nov;42(5):1458-64.
- Rivera-Rivera LA, Schubert T, Turski
P, et al. Changes in intracranial venous blood flow and pulsatility in
Alzheimer's disease: A 4D flow MRI study. J Cereb Blood Flow Metab. 2017
Jun;37(6):2149-2158.
- Allison, S.L., Koscik, R.L., Cary, R.P., et al. Comparison
of different MRI-based morphometric estimates for defining neurodegeneration
across the Alzheimer's disease continuum. NeuroImage: Clin. 2019 23, 101895.
- Patenaude, B., Smith, S.M., Kennedy, D., and Jenkinson M. A
Bayesian Model of Shape and Appearance for Subcortical Brain NeuroImage,
56(3):907-922, 2011.
- Schmidt P., Gaser C., Arsic M., et
al. An automated tool for detection of FLAIR-hyperintense white-matter lesions
in multiple sclerosis. Neuroimage. 2012;59:3774–3783.
- Betthauser TJ, Koscik RL, Jonaitis
EM, et al. Amyloid and tau imaging biomarkers explain cognitive decline from
late middle-age. Brain 2020; 143: 320–335.
- Racine AM,
Clark LR, Berman SE, et al. Associations between Performance on an Abbreviated
CogState Battery, Other Measures of Cognitive Function, and Biomarkers in
People at Risk for Alzheimer’s Disease. J Alzheimers Dis 2016; 54: 1395–1408.
- Iliff JJ,
Wang M, Zeppenfeld DM, et al. Cerebral arterial pulsation drives paravascular
CSF‐interstitial
fluid exchange in the murine brain. J Neurosci. 2013;33(46):18190‐9.
- Aldea R, Roy O Weller RO, Donna M
Wilcock DM, et al. Cerebrovascular Smooth Muscle Cells as the Drivers of
Intramural Periarterial Drainage of the Brain. Front Aging Neurosci. 2019 Jan 23;11:1